Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Vaccination for atherosclerosis: a novel therapeutic paradigm

  • Prediman K Shah
  • Kuang-Yuh Chyu
  • Gunilla N Fredrikson
  • Jan Nilsson
Publishing year: 2004
Language: English
Pages: 711-716
Publication/Series: Expert Review of Vaccines
Volume: 3
Issue: 6
Document type: Journal article
Publisher: Future Drugs Ltd

Abstract english

Numerous studies have identified a role for the innate and adaptive immune response in atherosclerosis; both pro- and antiatherogenic roles for the immune responses have been demonstrated. Common autoantigens against which an immune response has been identified in experimental and human models of atherosclerosis include oxidized low-density lipopoteins, beta2 glycoprotein 1 and heat shock protein 60. Activation of atheroprotective adaptive immune responses have been demonstrated for oxidized low-density lipoprotein-related antigens. Conversely, atheroprotection has been demonstrated with the induction of immune tolerance through activation of mucosal immunity to heat shock protein 65/60 and beta2 glycoprotein 1. Recent identification of specific immunoreactive antigenic epitopes in the apolipoprotein B-100 component of low density lipoproetin and early experimental observations have provided proof of concept that active vaccination using specific apolipoprotein B-100-related antigens may emerge as a novel immunomodulating atheroprotective strategy.


  • Cardiac and Cardiovascular Systems


  • Cardiovascular Research - Immunity and Athersosclerosis
  • ISSN: 1744-8395
E-mail: jan [dot] nilsson [at] med [dot] lu [dot] se

Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00